Lysosome-targeting chimera, method for preparing same, and pharmaceutical composition comprising same

Abstract

The present invention relates to a lysosome-targeting chimera, a method for preparing same, and a pharmaceutical composition comprising same. More specifically, the present invention provides: a lysosome-targeting chimera comprising a target protein-binding domain specifically binding to a cell surface molecule or an extracellular molecule, a ligand domain specifically binding to a lysosome-targeting molecule, and a linker between the target protein-binding domain and the ligand domain, wherein the linker includes a DBCO-azide conjugate moiety; a method for preparing the lysosome-targeting chimera, the method comprising a step for preparing a target protein-binding domain having an azide moiety and specifically binding to a cell surface molecule or an extracellular molecule, a step for preparing a ligand domain having a DBCO moiety and specifically binding to a lysosome-targeting molecule, and a step for mixing the target protein-binding domain and the ligand domain and binding same by a click reaction; and an immune checkpoint inhibitor and a pharmaceutical composition for treating cancer, which include the lysosome-targeting chimera according to the present invention.

Images